FutureChem's consolidated revenue for the first three quarters of this year rose 22.6% year over year to KRW 15.33 billion.


FutureChem's Q3 YTD Revenue Rises 22.6% YoY to KRW 15.3 Billion View original image

According to FutureChem on November 12, the company recorded revenue of KRW 4.7 billion and an operating loss of KRW 1.87 billion in the third quarter alone. Revenue increased 24.0% year over year and 10.1% quarter over quarter. Operating losses narrowed by 25.8% year over year and 41.8% quarter over quarter, thanks to increased revenue and improved selling, general and administrative expenses. The company is expected to achieve its highest-ever annual revenue this year, driven by growth in its existing radiopharmaceutical business and its affiliates.


The company is pursuing further clinical development of its prostate cancer treatment and diagnostic agent, as well as expanded domestic sales. On October 23, FutureChem disclosed topline results from the U.S. Phase 2a clinical trial of FC705, its prostate cancer treatment candidate. The objective response rate (ORR), based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), was 38.9%, while the proportion of patients whose prostate-specific antigen (PSA) levels fell by at least 50% (PSA50 response rate) was 58.8%.


The company plans to obtain the final clinical study report (CSR) this month and announce the objective response rate based on PSMA PET imaging assessments, along with key safety indicators. It will refine its follow-on development strategy based on the clinical results and continue discussions on global technology licensing. Prostate cancer diagnostic agent Prostavu (FC303) received domestic product approval in April and began sales in late August. 



FutureChem CEO Ji Daeyoon said, "We are strengthening the foundation for improved profitability through steady revenue growth in our existing radiopharmaceutical business and greater cost efficiency. We will focus our efforts on pursuing global technology licensing for FC705, applying for conditional domestic product approval next year, and ensuring the successful market entry of Prostavu, our prostate cancer diagnostic agent. In doing so, we will secure growth drivers and work to continually enhance corporate and shareholder value."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing